Draig Therapeutics focuses on developing innovative therapies that leverage advanced biotechnological approaches to address unmet medical needs. The company is dedicated to creating novel treatments that target specific disease mechanisms, utilizing a combination of proprietary platforms and cutting-edge research. Their pipeline includes a range of therapeutic candidates aimed at various conditions, showcasing their commitment to advancing healthcare through scientific innovation.

The technologies employed by Draig Therapeutics encompass a variety of methodologies, including targeted drug delivery systems and biologics designed to enhance therapeutic efficacy and minimize side effects. By integrating insights from molecular biology and pharmacology, Draig aims to optimize treatment outcomes for patients. Their emphasis on rigorous scientific validation ensures that their products are not only effective but also safe, reflecting their dedication to high standards in therapeutic development.

United Kingdom

Draig Therapeutics is a clinical-stage company with a mission to transform treatments in Neuropsychiatry. The company is leveraging its founders' unique scientific expertise in modulating the core glutamate / GABA pathways that play a critical role in neuropsychiatric diseases to advance a pipeline of groundbreaking therapies designed to address large unmet patient needs, including in Major Depressive Disorder (MDD).

Draig is the Welsh word for ‘dragon' and it reflects the company's origins in Wales. The name and logo were inspired by this heritage, reflecting its scientific roots stemming from Cardiff University.

Draig Therapeutics

Company Details